RVTY Stock Chart & Stats
$1900.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1900.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,644.85 - $1,946.36
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$210.30B
Enterprise Value$12.44K
Total Cash (Recent Filing)$860.32M
Total Debt (Recent Filing)$3.35B
Price to Earnings (P/E)53.1
Beta-0.20
Next Earnings
Aug 04, 2026EPS Estimate
21.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,559,780
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,927.65Price Target Upside1.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables + Installed Base ModelRevvity’s business model pairs capital instrument sales with high-margin recurring consumables, software and service contracts. That installed-base-driven repeat revenue supports predictable cash flow and customer lock-in, sustaining durable revenue streams as instrument penetration grows across labs and clinics.
Solid Cash GenerationConsistent absolute free cash flow and operating cash flow give Revvity flexibility for R&D, acquisitions, and buybacks. Strong FCF supports investment in software and instruments, funds portfolio optimization, and buffers swings in cyclical research and diagnostics demand over the medium term.
Software/ARR MomentumRapid ARR expansion and new software/AI product launches shift revenue toward higher-margin, recurring SaaS streams. Over months, rising software mix can improve margin stability, reduce cyclicality from instruments, and create scalable, predictable revenue complementary to consumables.
Bears Say
China Divestiture & Timing RiskSelling the China immunodiagnostics unit trims revenue and creates a near-term EPS headwind while proceeds aren’t realized until close. The LOI-stage sale adds execution, regulatory and timing uncertainty that can mute near-term growth and complicate operational planning through 2026–2027.
Weaker Cash-conversion TrendsAlthough FCF is sizable in absolute terms, conversion of earnings to cash has weakened materially. Persistently lower cash-conversion ratios suggest working-capital or collection pressure that can constrain reinvestment, reduce capital return capacity, and weaken resilience to demand shocks.
Volatile Profitability & Lower ReturnsMargins and returns remain below peak years and have shown volatility, including a 2023 loss. Subdued ROE and a step-down from earlier margin profiles indicate challenges in translating revenue into sustained higher returns, limiting long-term shareholder value creation unless structural improvements persist.
Revvity News
RVTY FAQ
What was Revvity, Inc.’s price range in the past 12 months?
Revvity, Inc. lowest stock price was $1644.85 and its highest was $1946.36 in the past 12 months.
What is Revvity, Inc.’s market cap?
Revvity, Inc.’s market cap is $210.30B.
When is Revvity, Inc.’s upcoming earnings report date?
Revvity, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 6 days.
How were Revvity, Inc.’s earnings last quarter?
Revvity, Inc. released its earnings results on May 05, 2026. The company reported $18.141 earnings per share for the quarter, beating the consensus estimate of $17.722 by $0.419.
Is Revvity, Inc. overvalued?
According to Wall Street analysts Revvity, Inc.’s price is currently Undervalued.
Does Revvity, Inc. pay dividends?
Revvity, Inc. does not currently pay dividends.
What is Revvity, Inc.’s EPS estimate?
Revvity, Inc.’s EPS estimate is 21.09.
How many shares outstanding does Revvity, Inc. have?
Revvity, Inc. has 111,559,780 shares outstanding.
What happened to Revvity, Inc.’s price movement after its last earnings report?
Revvity, Inc. reported an EPS of $18.141 in its last earnings report, beating expectations of $17.722. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revvity, Inc.?
Currently, no hedge funds are holding shares in MX:RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,927.65 (1.46% Upside)
$1,927.65 (1.46% Upside)
Blogger Sentiment
Bullish
MX:RVTY Sentiment 67%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.63%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
RVTY Company Deck
RVTY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by a better-than-expected Q1 (organic growth, margin and EPS beats), strong cash conversion, healthy software ARR trends, and a strategic decision to divest a underperforming China diagnostics business that should improve longer-term margins and growth. Near-term cautions include China market weakness, Q2 software cadence volatility, a ~$0.15 EPS headwind in 2026 from the divestiture (with proceeds not realized until 2027), and reduced FX tailwinds. Management emphasized operational cost initiatives and expected margin expansion into the second half of the year and into 2027, supporting an upbeat long-term outlook despite the identified near-term risks.View all MX:RVTY earnings summariesRVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$1,927.65
▲(1.46% Upside)